Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus PRAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus PRAZEPAM.
DORAL vs PRAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Prazepam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity at GABA-A receptors, leading to increased chloride ion influx, neuronal hyperpolarization, and central nervous system depression.
15-30 mg orally at bedtime, maximum 60 mg/day.
10-30 mg orally 3-4 times daily; maximum daily dose 60 mg.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Clinical Note
moderatePrazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone propionate."
Clinical Note
moderatePrazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Cyclosporine
Terminal elimination half-life: 36-200 hours (mean ~75 hours). Long half-life leads to accumulation with repeated dosing and prolonged sedation, especially in elderly or hepatic impairment.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Primarily renal (as conjugated metabolites, mainly oxazepam glucuronide): ~95%; fecal: ~5%.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Prazepam."